Type-2 diabetes drug market set to double by 2021
The diabetes drug market is looking robust thanks to a large pipeline of new products and an ever-increasing patient population.
The market for drugs designed to treat type-2 diabetes will almost double over the next ten years, experts have predicted.
Last year, the market in the US, France, Germany, Italy, Spain, the UK and Japan was valued at around $26 billion, but research and advisory firm Decision Resources expects this figure to rise to nearly $50 billion in 2021.
This is due to the rising number of people who need treatment for the lifestyle-related condition, as well as the large pipeline of products that are expected to enter the market during the period.
One of the most exciting classes of drugs in this field is SGLT-2 inhibitors, such as dapagliflozin (AstraZeneca/Bristol-Myers Squibb) - which is expected to launch in Europe later this year - and canagliflozin (Johnson & Johnson).
Dr Donny Wong, Decision Resources' therapeutic area director, revealed: "Interviewed thought leaders consider the SGLT-2 inhibitors the most interesting agents that will emerge during the forecast period based on their weight-loss efficacy, versatility and low risk of hypoglycaemia."
Strong growth should also continue in the DPP-IV inhibitor drug class, which Decision Resources claims will enjoy a 28 per cent share of the market by 2012.
Related News
-
News Women in Pharma: Hiring Across the Gender Divide
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News Revolutionising cancer treatment with mRNA-based therapeutics
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours. -
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ... -
News Choosing the Right CDMO Partner: A Comprehensive Guide
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance